AnaptysBio (NASDAQ:ANAB) Coverage Initiated by Analysts at Wolfe Research

Analysts at Wolfe Research started coverage on shares of AnaptysBio (NASDAQ:ANAB) in a research note issued on Tuesday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $25.00 price target on the biotechnology company’s stock. Wolfe Research’s target price would suggest a potential upside of 50.06% from the stock’s previous close.

Several other research firms have also recently weighed in on ANAB. UBS Group boosted their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. decreased their price target on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th. Wedbush reiterated an “outperform” rating and set a $40.00 price target on shares of AnaptysBio in a report on Monday. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a report on Monday, December 2nd. Finally, Truist Financial cut their target price on AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a report on Wednesday, December 18th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.08.

AnaptysBio Price Performance

Shares of AnaptysBio stock opened at $16.66 on Tuesday. The company’s 50 day moving average price is $17.38 and its two-hundred day moving average price is $27.01. The firm has a market capitalization of $506.96 million and a P/E ratio of -2.74. AnaptysBio has a fifty-two week low of $12.51 and a fifty-two week high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, beating the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The company had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. On average, analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

Insider Transactions at AnaptysBio

In other news, Director Ecor1 Capital, Llc purchased 6,646 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were acquired at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now owns 7,880,094 shares in the company, valued at approximately $102,047,217.30. The trade was a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 33.70% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Institutional investors have recently modified their holdings of the company. Values First Advisors Inc. bought a new stake in AnaptysBio during the 3rd quarter valued at $49,000. nVerses Capital LLC increased its position in shares of AnaptysBio by 700.0% during the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company’s stock worth $54,000 after acquiring an additional 1,400 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of AnaptysBio by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,452 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 644 shares during the last quarter. Point72 DIFC Ltd lifted its position in AnaptysBio by 680.5% in the 3rd quarter. Point72 DIFC Ltd now owns 6,127 shares of the biotechnology company’s stock valued at $205,000 after acquiring an additional 5,342 shares in the last quarter. Finally, SG Americas Securities LLC boosted its stake in AnaptysBio by 35.0% during the 4th quarter. SG Americas Securities LLC now owns 16,307 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 4,231 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.